Stockreport

Adamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment

Adamas Pharmaceuticals, Inc.  (ADMS) 
Last adamas pharmaceuticals, inc. earnings: 2/25 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.adamaspharma.com/investors
PDF EMERYVILLE, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the first patient has been enrolled in its pivot [Read more]